blood cells travel through a blood vessel

KCENTRA®

Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.

Product Information Educational Materials Conferences and Events Key Publications

Key Publications

Acquired Bleeding Publications

KCENTRA was approved by the United States (US) food and Drug Administration (FDA) on April 29, 2013. KCENTRA, under the trade name Beriplex or Confidex, has been approved in other countries since 1996. The specific drug product name that was used in the cited publications is referenced below:

Thromboembolism after treatment with 4 factor prothrombin complex concentrate or plasma for warfarin related bleeding

Kcentra_Go Graphical Abstract
Tap Image to view Graphical Abstract

Go et al. 2022
Request | Ask a Question | View Article

INR and vitamin K–dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma

Retrospective Analysis: INR and Vitamin K-Dependent Factor Levels After Vitamin K Antagonist Reversal With 4F-PCC or Plasma
Tap Image to view Graphical Abstract

Hood et al. 2022
Request | Ask a Question | View Article

Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies

Milling TJ Jr, et al., Ann Emerg Med 2016
Request | Ask a Question | View Article

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomized trial

Kcentra_Goldstein Graphical Abstract
Tap Image to view Graphical Abstract

Goldstein JN, et al., Lancet 2015
Request | Ask a Question | View Article

Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal

Refaai, MA, et al., Transfusion 2015
Request | Ask a Question | View Article

Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study

Kcentra_Sarode Graphical Abstract
Tap Image to view Graphical Abstract

Sarode R, et al., Circulation 2013
Request | Ask a Question | View Article

Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate. A prospective clinical trial of emergency anticoagulation reversal

Pabinger I, et al., Ann Hematol 2010
Request | Ask a Question | View Article

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial

Pabinger I, et al., Thromb Haemost 2008
Request | Ask a Question | View Article

Pharmacokinetics of BERIPLEX P/N prothrombin complex concentrate in healthy volunteers

Ostermann H, et al., Thromb Haemost 2007
Request | Ask a Question | View Article

Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage

Lorenz R, et al., Eur J Gastroenterol Hepatol 2003
Request | Ask a Question | View Article
The referenced CSL Behring product has not been approved by FDA for the use described in these publications, and the safety and effectiveness of the CSL Behring product has not been established for the use described in these publications.

Four-Factor Prothrombin Complex Concentrate (4F-PCC) for the Treatment of Oral Factor Xa Inhibitor-Associated Bleeding: A Meta-Analysis of Fixed Versus Variable Dosing

Four-Factor Prothrombin Complex Concentrate (4F-PCC) for the Treatment of Oral Factor Xa Inhibitor-Associated Bleeding: A Meta-Analysis of Fixed Versus Variable Dosing
Tap Image to view Graphical Abstract

Chiasakul et al 2023
Request | Ask a Question | View Article

Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants

Sarode et al. 2023
Request | Ask a Question | View Article

Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding

Muir et al 2024
Request | Ask a Question | View Article

Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates

Panos et al 2020
Request | Ask a Question | View Article

The referenced CSL Behring product has not been approved by FDA for the use described in these publications, and the safety and effectiveness of the CSL Behring product has not been established for the use described in these publications.

Prothrombin Complex Concentrate vs Plasma for Post–Cardiopulmonary Bypass Coagulopathy and Bleeding

Smith et al 2022
Request | Ask a Question | View Article

4-Factor Prothrombin Complex Concentrate (PCC4, Kcentra®) Protocol Reduces Blood Requirements for Heart Transplantation: A Novel Protocol 

Cleary et al 2016
Request | Ask a Question | View Article

Impact of Prothrombin Complex Concentrate on Blood Use, Cost, and Outcomes in Heart Transplantation  

Wu et al 2016
Request | Ask a Question | View Article

Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation  

Sun et al 2018
Request | Ask a Question | View Article

The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis 

Jehan et al 2018
Request | Ask a Question | View Article

toggle chat overlay
toggle chat overlay